USCWA
AVDL

U.S. Capital Wealth Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-450
Closed -$3.22K – 701
2022
Q4 		$3.22K Buy
+450
New +$3.15K ﹤0.01% 1446

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

U.S. Capital Wealth Advisors's AVDL Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2023, closing a stake of 450 shares — an estimated $3.22K sold.

U.S. Capital Wealth Advisors first reported a position in AVDL in Q4 2022 and held it in 1 quarter. The position peaked at $3.22K in Q4 2022. 93 funds tracked by Wall St. Rank hold AVDL as of Q1 2023.

  • U.S. Capital Wealth Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • U.S. Capital Wealth Advisors sold 450 Avadel Pharmaceuticals shares in Q1 2023, an estimated $3.22K.
  • U.S. Capital Wealth Advisors first reported a position in Avadel Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • U.S. Capital Wealth Advisors's Avadel Pharmaceuticals position peaked at $3.22K in Q4 2022.
  • 93 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.